Scott, O., Lindsay, K., Erwood, S., Roifman, C.M., Cohn, R.D., Ivakine, E.A. Heterozygous cell models of STAT1 gain-of-function reveal a broad spectrum of interferon-signature gene transcriptional responses BioRxiv (2020).


Erwood, S., Laselva, O., Bily, T.M.I., Brewer, R.A.,  Rutherford, A.H., Bear, C.E., Ivakine, E.A. Allele-specific prevention of nonsense-mediated decay in cystic fibrosis using homology-independent genome editing Molecular Therapy – Methods and Clinical Development 17:1118-1128 (2020).


Erwood, S., Gu, B. Embryo-based large fragment knock-in in mammals: why, how and what’s next. Genes (Basel.) 11(2):140 (2020).


Erwood, S., Brewer, R.A., Bily, T.M.I., Maino, E., Zhou, L., Cohn, R.D., Ivakine, E.A. Modeling Niemann–Pick disease type C in a human haploid cell line allows for patient variant characterization and clinical interpretation. Genome Research 29(12):2010-2019 (2019).


Garcia, B., Lee, J., Edraki, A., Hidalgo-Reyes, Y., Erwood, S., Mir, A., Trost, C.N., Seroussi, U., Stanley, S.Y., Cohn, R.D., Claycomb, J.M., Sontheimer, E.J., Maxwell, K.L., Davidson, A.R. Anti-CRISPR AcrIIA5 potently inhibits all Cas9 homologs used for genome editing. Cell Reports 29(7):1739-1746.e5. (2019).

Kemaladewi, D. U., Bassi, P. S., Erwood, S., Al-Basha, D., Gawlik, K. I., Lindsay, K., Hyatt, E., Kember, R.Place, K. M., Marks, R., Durbeej, M., Prescott, S.A., Ivakine, E. A., Cohn, R. D. A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene. Nature 572(7767):125-130 (2019).


Kemaladewi, D. U., Bassi, P. S., Lindsay, K., Erwood, S., Hyatt, E., Place, K. M., Marks, R., Gawlik, K. I., Durbeej, M., Ivakine, E. A., Cohn, R. D. A mutation-independent approach via transcriptional upregulation of disease modifier gene rescues muscular dystrophy in vivo. bioRxiv 286500 doi: 


Kemaladewi, D. U., Benjamin, J. S., Hyatt, E., Ivakine, E. A., Cohn, R. D. Increased polyamines as protective disease modifiers in congenital muscular dystrophy. Human Molecular Genetics 27, 1905–1912 (2018).


Dowling, J. J., D Gonorazky, H., Cohn, R. D., Campbell, C. Treating pediatric neuromuscular disorders: The future is now. Am. J. Med. Genet. A 176, 804–841 (2018).


Kemaladewi, D. U., Maino, E., Hyatt, E., Hou, H., Ding, M., Place, K. M., Xinyi, Z., Bassi, P. S., Baghestani, Z., Deshwar, A. G., Merico, D., Xiong, H. Y., Frey, B. J., Wilson, M. D., Ivakine, E. A., Cohn, R. D. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nature Medicine 23, 984–989 (2017).


Wong, T. W. Y. & Cohn, R. D. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy. Current Gene Therapy 17, 301–308 (2017).


Kemaladewi, D. U. & Cohn, R. D. Exon Snipping in Duchenne Muscular Dystrophy. Trends Mol Med 22, 187–189 (2016).


Wojtal, D., Kemaladewi, D. U., Malam, Z., Abdullah, S., Wong, T. W., Hyatt, E., Baghestani, Z., Pereira, S., Stavropoulos, J., Mouly, V., Mamchaoui, K., Muntoni, F., Voit, T., Gonorazky, H. D., Dowling, J. J., Wilson, M. D., Mendoza-Londono, R., Ivakine, E. A., Cohn, R. D. Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders. Am. J. Hum. Genet. 98, 90–101 (2016).


Malam, Z. & Cohn, R. D. Stem cells on alert: priming quiescent stem cells after remote injury. Cell Stem Cell 15, 7–8 (2014).


Andres-Mateos, E., Brinkmeier, H., Burks, T. N., Mejias, R., Files, D. C., Steinberger, M., Soleimani, A., Marx, R., Slimmers, J. L., Lin, B., Finager Hedderick, E., Marr, T. G., Lin, B. M., Hourdé, C., Leinwand, L. A., Kuhl, D., Föller, M., Vogelsang, S., Hernandez-Diaz, I., Vaughan, D. K., Alvarez de la Rosa, D., Lang, F., Cohn, R. D.  Activation of serum/glucocorticoid-induced kinase 1 (SGK1) is important to maintain skeletal muscle homeostasis and prevent atrophy. EMBO Mol Med 5, 80–91 (2013).


Cohn, R. D., Liang, H.-Y., Shetty, R., Abraham, T. & Wagner, K. R. Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscular Disorders 17, 290–296 (2007).


Cohn, R. D., Van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T., Gamradt, M., ap Rhys, C. M., Holm, T. M., Loeys, B. L., Ramirez, F., Judge, D. P., Ward, C. W., Dietz, H. C. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nature Medicine 13, 204–210 (2007).


Cohn, R. D., Henry, M. D., Michele, D. E., Barresi, R., Saito, F., Moore, S. A., Flanagan, J. D., Skwarchuk, M. W., Robbins, M. E., Mendell, J. R., Williamson, R. A., Campbell, K. P. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110, 639–648 (2002).


Moore, S. A., Saito, F., Chen, J., Michele, D. E., Henry, M. D., Messing, A., Cohn., R. D., Ross-Barta, S. E., Westra, S., Williamson, R. A., Hoshi, T., Campbell, K. P. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418, 422–425 (2002).


Michele, D. E., Barresi, R., Kanagawa, M., Saito, F., Cohn, R. D., Satz, J. S., Dollar, J., Nishino, I., Kelley, R. I., Somer, H., Straub, V., Mathews, K. D., Moore, S. A., Campbell, K. P. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418, 417–422 (2002).